title: Prospective study of statin use and risk of Parkinson disease.
abstract: OBJECTIVE
  To prospectively examine whether use of statins is associated with altered risk of Parkinson disease (PD).
  
  
  METHODS
  A prospective study including 38 192 men and 90 874 women participating in 2 ongoing US cohorts, the Health Professional Follow-up Study and the Nurses' Health Study, was conducted. Information on regular cholesterol-lowering drug use (≥2 times/wk) was collected in 1994 in both cohorts via questionnaire. Relative risks (RRs) and 95% CIs were computed using Cox proportional hazards models adjusting for age, smoking, caffeine intake, duration of hypercholesterolemia, and other covariates.
  
  
  METHODS
  Incident PD.
  
  
  RESULTS
  During 12 years of follow-up (1994-2006), we documented 644 incident PD cases (338 women and 306 men). The risk of PD was lower among current statin users (adjusted pooled RR = 0.74; 95% CI, 0.54-1.00; P = .049) relative to nonusers. A significant association was observed in participants younger than 60 years at baseline (adjusted pooled RR = 0.31; 95% CI, 0.11-0.86; P = .02) but not among those who were older (adjusted pooled RR = 0.83; 95% CI, 0.60-1.14; P = .25) (P for interaction = .03).
  
  
  CONCLUSIONS
  We found that regular use of statins was associated with a modest reduction in PD risk. The possibility that some statins may reduce PD risk deserves further consideration.
authors.affiliation: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. xiang.gao@channing.harvard.edu
authors.forename: Xiang
authors.initials: X
authors.lastname: Gao
authors.forename: Kelly C
authors.initials: KC
authors.lastname: Simon
authors.forename: Michael A
authors.initials: MA
authors.lastname: Schwarzschild
authors.forename: Alberto
authors.initials: A
authors.lastname: Ascherio
mesh_terms: D000328:Adult; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy; D007052:Ibuprofen / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010300:Parkinson Disease / Q000453:epidemiology* / Q000517:prevention & control*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012306:Risk; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007052:Ibuprofen